NEW YORK (GenomeWeb) – GenePeeks announced today that it has partnered with egg donation agency The Donor Solution and gestational carrier service 3 Sisters Surrogacy to provide preconception genetic screening to prospective parents.
GenePeeks will provide Donor Solution and 3 Sisters clients with access to its Virtual Progeny Analytics screening approach, which uses simulated DNA information from two would-be parents to predict the future genome of a child prior to conception. For every mutation this approach models in the hypothetical baby genomes, GenePeeks computes a variant gene dysfunction score that predicts gene function and associated disease risk. This is different from carrier screening, which identifies parental carrier status, in that GenePeeks' approach looks at a future child's true risk of inheriting disease, the company said.
The service is offered through GenePeeks' CLIA-certified clinical laboratory.
Further terms of the agreements were not disclosed.
"We are thrilled to partner with The Donor Solution and 3 Sisters Surrogacy, two organizations that share our unrelenting commitment to provide outstanding support on the complicated path of starting a family," GenePeeks Cofounder and CEO Anne Morriss said in a statement. "In addition to reaching more families, these collaborations will allow us to expand our physician network and increase patient access to our next generation technology."
GenePeeks partnered with Reproductive Medicine Associates of New York in March 2016 to recruit patients for a study evaluating the clinical performance of GenePeeks' pre-conception risk testing in comparison to expanded traditional carrier screening. And in 2014, GenePeeks launched Matchright, a version of its test focused on helping women choose sperm donors.